US4913837A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Heterocyclic compounds
Assignee: Merck Patent GmbH
•
Filing: 1986-12-18
•
Granted: 1990-04-03
•
Expires: 2006-12-18
Abstract
Abstract Heterocyclic compounds of the formula I R.sup.1 -A.sup.1 -Z.sup.1 -A.sup.2 -[Z.sup.2 -A.sup.3 ].sub.n -R.sup.2I wherein R 1 , R 2 , A 1 , A 2 , A 3 , Z 1 , Z 2 and n are defined in claim 1, can be used as components of liquid-crystalline phases.
Inventors
- 👤 George W. Gray
- 👤 Kenneth J. Toyne
- 👤 David Lacey
- 👤 Michael P. Burrow
- 👤 Rudolf Eidenschink
- 👤 Andreas Wachtler
- 👤 Georg Weber
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-31 23:09
CPC Classifications
C; C07; C07D; C07D213/00; C07D213/02; C07D213/04; C07D213/06; C07D213/16; C07D213/24; C07D213/26; C07D213/28; C07D213/30; C07D213/54; C07D213/55; C07D213/57; C07D241/00; C07D241/02; C07D241/10; C07D241/12; C07D241/14; C07D241/18; C07D241/24; C09; C09K; C09K19/00; C09K19/04; C09K19/06; C09K19/34; C09K19/3441; C09K19/3444; C09K19/345; C09K19/3452
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
122 words
In a liquid crystalline phase comprising at least two liquid crystal components, the improvement wherein at least one liquid crystal component is a pyridine compound of formula Ien R.sup.1 -Py-Phe-Z.sup.2 -Cy-R.sup.2 Ien wherein R 1 and R 2 are each independently of each other alkyl of 1-15 C atoms, wherein one or two non-adjacent CH 2 groups can also be replaced by O atoms and/or --CO-- groups and/or --O--CO-- groups and/or --CO--O-- groups and/or --CHCN-- and/or --CH--halogen groups, and one of the radicals R 1 and R 2 can also be F, Cl, Br, or CN; is pyridine-2,5-diyl; Phe is a 1,4-phenylene group which is unsubstituted or monosubstituted by F; Z 2 is --CO--O-- or --O--CO--; and Cy is a 1,4-cyclohexylene group.
Claim 2
Dependent Claim
122 words
In a liquid crystalline phase comprising at least two liquid crystal components, the improvement wherein at least one liquid crystal component is a pyridine compound of formula Ien R.sup.1 -Py-Phe-Z.sup.2 -Cy-R.sup.2 Ien wherein R 1 and R 2 are each independently of each other alkyl of 1-15 C atoms, wherein one or two non-adjacent CH 2 groups can also be replaced by O atoms and/or --CO-- groups and/or --O--CO-- groups and/or --CO--O-- groups and/or --CHCN-- and/or --CH--halogen groups, and one of the radicals R 1 and R 2 can also be F, Cl, Br, or CN; is pyridine-2,5-diyl; Phe is a 1,4-phenylene group which is unsubstituted or monosubstituted by F; Z 2 is --CO--O-- or --O--CO--; and Cy is a 1,4-cyclohexylene group.
Claim 3
Dependent Claim
13 words
A phase of claim 1, wherein Z 2 in formula Ien is --O--CO--.
Claim 4
Dependent Claim
29 words
A phase of claim 1, wherein R 1 and R 2 are each alkyl of 1-15 C atoms, alkyloxy, or oxaalkyl having 1-14 C atoms in the alkyl part.
Claim 5
Dependent Claim
9 words
A phase of claim 1, wherein Phe is 1,4-phenylene.
Claim 6
Dependent Claim
32 words
A phase of claim 1, wherein the pyridine compound of formula Ien has the following structure ##STR27## wherein R 1 and R 2 are each an alkyl group of 1-15 C atoms.
Claim 7
Dependent Claim
34 words
A phase of claim 5, wherein said pyridine compound is 4-(5-Nonylpyridin-2-yl)-phenyl trans-4-propylcyclohexanecarboxylate 4-(5-Nonylpyridin-2-yl)-phenyl trans-4-butylcyclohexanecarboxylate 4-(5-Nonylpyridin-2-yl)-phenyl trans-4-pentylcyclohexanecarboxylate 4-(5-Nonylpyridin-2-yl)-phenyl trans-4-hexylcyclohexanecarboxylate 4-(5-Nonylpyridin-2-yl)-phenyl trans-4-heptylcyclohexanecarboxylate 4-(5-Nonylpyridin-2-yl)-phenyl trans-4-octylcyclohexanecarboxylate 4-(5-Octylpyridin-2-yl)-phenyl trans-4-propylcyclohexanecarboxylate 4-(5-Octylpyridin-2-yl)-phenyl trans-4-butylcyclohexanecarboxylate 4-(5-Octylpyridin-2-yl)-phenyl trans-4-pentylcyclohexanecarboxylate 4-(5-Octylpyridin-2-yl)-phenyl trans-4-hexylcyclohexanecarboxylate 4-(5-Octylpyridin-2-yl)-phenyl trans-4-heptylcyclohexanecarboxylate 4-(5-Octylpyridin-2-yl)-phenyl trans-4-octylcyclohexanecarboxylate.
Claim 8
Dependent Claim
34 words
A phase of claim 5, wherein said pyridine compound is 4-(5-Heptylpyridin-2-yl)-phenyl trans-4-propylcyclohexanecarboxylate 4-(5-Heptylpyridin-2-yl)-phenyl trans-4-butylcyclohexanecarboxylate 4-(5-Heptylpyridin-2-yl)-phenyl trans-4-pentylcyclohexanecarboxylate 4-(5-Heptylpyridin-2-yl)-phenyl trans-4-hexylcyclohexanecarboxylate 4-(5-Heptylpyridin-2-yl)-phenyl trans-4-heptylcyclohexanecarboxylate 4-(5-Heptylpyridin-2-yl)-phenyl trans-4-octylcyclohexanecarboxylate 4-(5-Hexylpyridin-2-yl)-phenyl trans-4-propylcyclohexanecarboxylate 4-(5-Hexylpyridin-2-yl)-phenyl trans-4-butylcyclohexanecarboxylate 4-(5-Hexylpyridin-2-yl)-phenyl trans-4-pentylcyclohexanecarboxylate 4-(5-Hexylpyridin-2-yl)-phenyl trans-4-hexylcyclohexanecarboxylate 4-(5-Hexylpyridin-2-yl)-phenyl trans-4-heptylcyclohexanecarboxylate 4-(5-Hexylpyridin-2-yl)-phenyl trans-4-octylcyclohexanecarboxylate.
Claim 9
Dependent Claim
34 words
A phase of claim 5, wherein said pyridine compound is 4-(5-Pentylpyridin-2-yl)-phenyl trans-4-propylcyclohexanecarboxylate 4-(5-Pentylpyridin-2-yl)-phenyl trans-4-butylcyclohexanecarboxylate 4-(5-Pentylpyridin-2-yl)-phenyl trans-4-pentylcyclohexanecarboxylate 4-(5-Pentylpyridin-2-yl)-phenyl trans-4-hexylcyclohexanecarboxylate 4-(5-Pentylpyridin-2-yl)-phenyl trans-4-heptylcyclohexanecarboxylate 4-(5-Pentylpyridin-2-yl)-phenyl trans-4-octylcyclohexanecarboxylate 4-(5-Butylpyridin-2-yl)-phenyl trans-4-propylcyclohexanecarboxylate 4-(5-Butylpyridin-2-yl)-phenyl trans-4-butylcyclohexanecarboxylate 4-(5-Butylpyridin-2-yl)-phenyl trans-4-pentylcyclohexanecarboxylate 4-(5-Butylpyridin-2-yl)-phenyl trans-4-hexylcyclohexanecarboxylate 4-(5-Butylpyridin-2-yl)-phenyl trans-4-heptylcyclohexanecarboxylate 4-(5-Butylpyridin-2-yl)-phenyl trans-4-octylcyclohexanecarboxylate
Claim 10
Dependent Claim
34 words
A phase of claim 5, wherein said pyridine compound is 4-(5-Propylpyridin-2-yl)-phenyl trans-4-propylcyclohexanecarboxylate 4-(5-Propylpyridin-2-yl)-phenyl trans-4-butylcyclohexanecarboxylate 4-(5-Propylpyridin-2-yl)-phenyl trans-4-pentylcyclohexanecarboxylate 4-(5-Propylpyridin-2-yl)-phenyl trans-4-hexylcyclohexanecarboxylate 4-(5-Propylpyridin-2-yl)-phenyl trans-4-heptylcyclohexanecarboxylate 4-(5-Propylpyridin-2-yl)-phenyl trans-4-octylcyclohexanecarboxylate 4-(5-Ethylpyridin-2-yl)-phenyl trans-4-propylcyclohexanecarboxylate 4-(5-Ethylpyridin-2-yl)-phenyl trans-4-butylcyclohexanecarboxylate 4-(5-Ethylpyridin-2-yl)-phenyl trans-4-pentylcyclohexanecarboxylate 4-(5-Ethylpyridin-2-yl)-phenyl trans-4-hexylcyclohexanecarboxylate 4-(5-Ethylpyridin-2-yl)-phenyl trans-4-heptylcyclohexanecarboxylate 4-(5-Ethylpyridin-2-yl)-phenyl trans-4-octylcyclohexanecarboxylate.
Claim 11
Dependent Claim
20 words
In an electro-optical display element comprising a liquid crystalline phase, the improvement wherein the phase is one of claim 1.
References Cited (Backward Citations)
DE240386C
Cited
US4256656A
Cited
GB2092169A
Cited
JPS58121272A
Cited
JPS59144771A
Cited
US4592857A
Cited
JPS6092276A
Cited
JPS60149564A
Cited
US4713197A
Cited
US4659502A
Cited
GB2153345A
Cited
JPS60163865A
Cited
JPS60199882A
Cited
US4668426A
Cited
US4642199A
Cited
US4744918A
Cited
US4684220A
Cited
JPS6124571A
Cited
US4659500A
Cited
WO1986004060A1
Cited
US4776973A
Cited
US4684477A
Cited
JPS6271A
Cited
US4721367A
Cited
JPS61246167A
Cited
US4834904A
Cited
DE3515373A1
Cited
WO1986006401A1
Cited
US4820839A
Cited
DE3518734A1
Cited
US4668425A
Cited
EP0206228A2
Cited
JPS6222889A
Cited
US4753752A
Cited
JPS62155257A
Cited
US4723018A
Cited
JPS62172090A
Cited
JPS62172089A
Cited
US4772416A
Cited
US4752413A
Cited
US4826979A
Cited
JPS6348254A
Cited
JPS6381193A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-04-02 | 1993-10-02 | 1994-04-03 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-04-02 | 1997-10-02 | 1998-04-03 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-04-02 | 2001-10-02 | 2002-04-03 | $7700.00 | Window Closed / Lapsed |